Summary
This paper updates the results of the clinical trial to examine the efficacy of exogenous leukocyte interferon therapy as adjuvant treatment for osteosarcoma. So far the incidence of metastases is lower and the survival rate is better for the interfer-on-treated group than for the concurrent control group. The number of treated patients is too small at present to allow proper statistical calculations to be made.
This study was supported by the Cancer Society of Stockholm, the Swedish Cancer Society, and Dagmar Harrelgren’s Fund
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adamson U, Aparisi T, Broström LÅ et al. (1979) Interferon treatment of human osteosarcoma. Study week of the Pontifical Academy of Sciences, Vatican city, Oct. 17–21, 1977. The role of non-specific immunity in the prevention and treatment of cancer. Pontif Accad Sci Scripta Varia 43:383–406
Adamson U, Aparisi T, Broström LÅ et al. (1979) Adjuvant interferon treatment of human osteosarcoma. EORTC Annual Meeting June 21–24, 1978, Paris. Recent Results Cancer Res 68:40–44
Broström LÅ (1979) On the natural history of osteosarcoma. Acta Orthop Scand [Suppl] 183:1–38
Broström LÅ, Ingimarsson S, Strander H, Söderberg G (to be published) Adjuvant interferon treatment and late development of cerebral metastases in a patient with osteosarcoma. Acta Orthop Scand
Cantell K, Hirvonen S (1978) Large scale production of human leukocyte interferon containing 108 units per ml. J Gen Virol 39:541–543
Cantell K, Strander H (1977) Human leucocyte interferon for clinical use. In: Högman CF, Lindahl-Kiessling K, Wigzell H (eds) Blood leucocytes, function and use in therapy. Almqvist & Wicksell, Stockholm, pp 73–75
Einhorn S, Blomgren H, Strander H (1978) Interferon and spontaneous cytotoxicity in man. II. Studies in patients receiving exogenous leukocyte interferon. Acta Med Scand 204:477–483
Einhorn S, Blomgren H, Cantell K, Strander H (1979) Effect of prolonged in vivo administration of leukocyte interferon on the mitogen responsiveness of human lymphocytes. Acta Med Scand 206:345–350
Einhorn S, Blomgren H, Strander H (to be published) Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon. Int J Cancer
Einhorn S, Blomgren H, Strander H (to be published) Effect of one intramuscular injection of human leukocyte interferon on blood leukocyte counts and proportion of lymphocytes forming E-, EA-, and EAC-rosettes. Int Arch Allergy Appl Immunol
Ingimarsson S, Strander H (1980) The frequency of acute infections in patients receiving interferon. In: Khan A, Hill NO, Dorn GL (eds) Interferon: Properties and clinical uses. Leland Fikes, Dallas, pp 633–644
Ingimarsson S, Cantell K, Strander H (1979) Symptomatic side-effects in patients receiving long-term therapy with human leukocyte interferon. J Infect Dis 140:560–563
Mogensen KE, Cantell K (1977) Production and preparation of human leukocyte interferon. Pharmacol Ther [C] 1:369–381
Nilsonne U, Strander H (to be published) Clinical experience of interferon treatment in osteosarcoma. 12th International Immunobiological Symposium. Yugoslav Academy of Sciences and Arts. Symposium on interferon, 1979
Strander H, Cantell K, Jakobsson PÅ, Nilsonne U, Soderberg G (1974) Exogenous interferon therapy of osteogenic sarcoma. Acta Orthop Scand 45:958
Strander H, Cantell K, Ingimarsson S, Jakobsson PÅ, Nilsonne U, Soderberg G (1975) Interferon treatment of osteogenic sarcoma. 3rd International Congress for Virology. Madrid, Sept. 10–17
Strander H, Cantell K, Ingimarsson I, Jakobsson PÅ, Nilsonne U, Söderberg G (1975) Interferon treatment of osteogenic sarcoma. 7th Meeting of the International Society of Pediatric Oncology. Stockholm, Sept. 17–20
Strander H, Cantell K, Carlström G, Ingimarsson S, Jakobsson P, Nilsonne U (1976) Acute infections in interferon-treated patients with osteosarcoma: Preliminary report of a comparative study. J Infect Dis 133: A245-A248
Strander H, Cantell K, Ingimarsson S, Jakobsson PÅ, Nilsonne U, Söderberg G (1977) Interferon treatment of osteogenic sarcoma: A clinical trial. Conference on “Modulation of host immune resistance in the prevention or treatment of induced neoplasias”, Dec. 9–11, 1974. Fogarty Int Center Proc 28: 377–381
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Strander, H. et al. (1982). Adjuvant Interferon Treatment of Human Osteosarcoma. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive